NCT07893535
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Dose Escalation Phase: Number of Participants with Dose-limiting Toxicities (DLTs)
Timeframe: Up to approximately 1 month
Dose Escalation Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Timeframe: From first dose of study drug until 30 days after last dose, up to approximately 24 months.
Dose Expansion Phase: Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months
Secondary (9)
Dose Escalation Phase: Objective Response Rate (ORR)
Duration of Response (DOR)
Disease Control Rate (DCR) at Week 12 and Week 24
Dose-Expansion Phase: Progression-free Survival (PFS)
Serum Concentration of BON-106
Show 4 moreShow less
Maximum Observed Concentration of BON-106
Area Under the Concentration-time Curve (AUC) of BON-106
Elimination Half-life (t1/2) of BON-106
Dose- Expansion Phase: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Arms and interventions
Phase 1a Dose EscalationExperimental
Sequential cohorts of increasing dose levels of BON-106 will be evaluated.
Phase 1b Dose ExpansionExperimental
Participants with selected advanced solid tumors will receive BON-106 at the selected dose(s).
Drugs: BON-106